Pozen seeks FDA approval for layered aspirin cardiovascular treatment

For patients with cardiovascular disease, aspirin has become a standard of care in preventing a second heart attack or stroke, but for some, side effects can include gastrointestinal bleeding. Pozen ($POZN) submitted an application with the FDA for a tablet that combines the gastrointestinal drug omeprazole and an asipirin core coated with a pH-sensitive material. The layered treatment would allow patients to undergo aspirin therapy without the complications, according to the company. Release